EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain

Paulina Maravilla-Herrera, María Merino, Santiago Alfonso Zamora, Jesús Balea Filgueiras, José Manuel Carrascosa Carrillo, Olga Delgado Sánchez, Francisco Dolz Sinisterra, Antonio García-Ruiz, Pedro Herranz Pinto, Antonio Manfredi, José Martínez Olmos, Paloma Morales de Los Ríos Luna und 3 weitere

Frontiers in Public Health · 26.01.2023 · 11

DOI: 10.3389/fpubh.2023.1000776 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Public Health, online erschienen am 26.01.2023. Verfasst von Paulina Maravilla-Herrera und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Outcomes Research, Weber, Madrid, Spain. Hauptthemen laut MEDLINE: Quality of Life, Psoriasis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UCB Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Psoriasis is a chronic disease involving the skin, which significantly impacts the quality of life. Disease severity and treatment efficacy (i.e., response) are assessed through the Psoriasis Area and Severity Index (PASI). A PASI 75 response, i.e., an improvement of at least 75% with respect to the baseline PASI score, has traditionally been used as a therapeutic benchmark in clinical trials. Therapeutic advances have made PASI 90 or PASI 100 responses possible in most patients treated with some biologics. A greater response may generate social value beyond clinical outcomes that would benefit both patients and society.

Methods

A 1-year economic model was applied to estimate the impact of having a PASI 75, PASI 90, or PASI 100 response in four areas of analysis (quality of life, activities of daily living, work productivity, and out-of-pocket expenditures) and the social value of having a PASI 90 or PASI 100 response in comparison with a PASI 75 response. A mixed-methods approach based on the scientific literature, a focus group with patient, and an advisory committee with psoriasis stakeholders was used. The model included three different scenarios: having a PASI 90 vs a PASI 75 response; a PASI 100 vs a PASI 90 response; and a PASI 100 vs a PASI 75 response. A sensitivity analysis was included.

Results

The annual economic impact per patient with moderate-to-severe plaque psoriasis having a PASI 75 response was estimated at Ł 6,139, mainly related to labour productivity losses and quality of life reductions. Having a PASI 90 or a PASI 100 response would reduce this impact to €3,956 or €1,353, respectively. Accordingly, the social value of having a PASI 90 instead of a PASI 75 response was estimated at €2,183, and €4,786 with a PASI 100 response.

Discussion

A PASI 90 or PASI 100 response would have a lower economic impact and a greater social value than a PASI 75 response for patients with moderate-to-severe plaque psoriasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifePsoriasisHumansSpainActivities of Daily LivingSocial Values

Stichwörter der Autor:innen

Psoriasis Area and Severity Index (PASI)activities of daily livingout-of-pocket (OOP) expensespsoriasisquality of lifesocial returnsocioeconomic impact

Autor:innen und Institutionen

  • Department of Health Outcomes Research, Weber, Madrid, Spain.
  • Department of Management, Psoriasis and Psoriatic Arthritis Patient and Family Association (Acción Psoriasis), Barcelona, Spain.
  • Department of Pharmacy, Ferrol University Hospital Complex, La Coruña, Spain.
  • Department of Dermatology, Germans Trias i Pujol University Hospital, Badalona, Spain.
  • Department of Management, Spanish Society of Hospital Pharmacy (SEFH), Madrid, Spain.
  • Department of Pharmacy, Son Espases University Hospital, Illes Balears, Spain.

Förderung

  • UCB Pharma

Zitieren

APA

Maravilla-Herrera, P., Merino, M., Alfonso Zamora, S., Balea Filgueiras, J., Carrascosa Carrillo, J. M., Delgado Sánchez, O., Dolz Sinisterra, F., García-Ruiz, A., Herranz Pinto, P., Manfredi, A., Martínez Olmos, J., Morales de Los Ríos Luna, P., Puig, L., Ros, S., & Hidalgo-Vega, Á. (2023). The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain. Frontiers in Public Health, 11. https://doi.org/10.3389/fpubh.2023.1000776

Vancouver

Maravilla-Herrera P, Merino M, Alfonso Zamora S, Balea Filgueiras J, Carrascosa Carrillo JM, Delgado Sánchez O, et al. The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain. Frontiers in Public Health. 2023;11. doi:10.3389/fpubh.2023.1000776

BibTeX
@article{MaravillaHerrera2023,
  author = {Maravilla-Herrera, Paulina and Merino, María and Alfonso Zamora, Santiago and Balea Filgueiras, Jesús and Carrascosa Carrillo, José Manuel and Delgado Sánchez, Olga and Dolz Sinisterra, Francisco and García-Ruiz, Antonio and Herranz Pinto, Pedro and Manfredi, Antonio and Martínez Olmos, José and Morales de Los Ríos Luna, Paloma and Puig, Lluís and Ros, Sandra and Hidalgo-Vega, Álvaro},
  title = {The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain},
  journal = {Frontiers in Public Health},
  year = {2023},
  volume = {11},
  doi = {10.3389/fpubh.2023.1000776}
}
Kostenlos starten →